Monovalent SARS-CoV-2 mRNA Vaccine Does not Boost Omicron-Specific Immune Response in Diabetic and Control Pediatric Patients.
Alan Sariol, Molly A Vickers, Shannon M Christensen, Daniela Weiskopf, Alessandro Sette, Andrew W Norris, Michael J Tansey, Catherina T Pinnaro, Stanley Perlman
Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Alan SariolDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA.
Molly A VickersDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA.
Shannon M ChristensenDepartment of Pediatrics-Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Andrew W NorrisDepartment of Pediatrics-Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, USA.
Michael J TanseyDepartment of Pediatrics-Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, USA.
Catherina T PinnaroDepartment of Pediatrics-Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, USA.
Stanley PerlmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA.ORCID 0000-0003-4213-2354
University of Iowa · USLa Jolla Institute for Immunology · US
Funding
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5M
Molecular and Cellular Research to Advance Childhood HealthK12HD027748 · NICHD · UNIVERSITY OF IOWA · PI ALEXANDER G BASSUK · 2002 to 2026
$9.2M
INTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAMT32AI007260 · NIAID · UNIVERSITY OF IOWA · PI BUTLER, NOAH SULLIVAN, WU, LI · 1986 to 2023
$5.7M
Role of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7M
Early Pathogenesis of Cystic Fibrosis Related DiabetesRC2DK124207 · NIDDK · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F, NORRIS, ANDREW W · 2021 to 2023
$4.5M
Splanchno-Hormonal Mechanisms of Cystic Fibrosis Related DiabetesR01DK115791 · NIDDK · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F, NORRIS, ANDREW W · 2018 to 2021
While the immunogenicity of SARS-CoV-2 vaccines has been well described in adults, pediatric populations have been less studied. In particular, children with type 1 diabetes are generally at elevated risk for more severe disease after infections, but are understudied in terms of COVID-19 and SARS-CoV-2 vaccine responses. We investigated the immunogenicity of COVID-19 mRNA vaccinations in 35 children with type 1 diabetes (T1D) and 23 controls and found that these children develop levels of SARS-CoV-2 neutralizing antibody titers and spike protein-specific T cells comparable to nondiabetic children. However, in comparing the neutralizing antibody responses in children who received 2 doses of mRNA vaccines (24 T1D; 14 controls) with those who received a third, booster dose (11 T1D; 9 controls), we found that the booster dose increased neutralizing antibody titers against ancestral SARS-CoV-2 strains but, unexpectedly, not Omicron lineage variants. In contrast, boosting enhanced Omicron variant neutralizing antibody titers in adults.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Monovalent SARS-CoV-2 mRNA Vaccine Does not Boost Omicron-Specific Immune Response in Diabetic and Control Pediatric Patients. · full record | OpenQuestion